SEC Filings
Standard BioTools Completes Microfluidics Sale To ARCHIMED, Which Renames It Biomark Scientific
The healthcare investment firm, which manages €15 billion, now owns the unit, and a new chief commercial officer has been named.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The healthcare investment firm, which manages €15 billion, now owns the unit, and a new chief commercial officer has been named.
Earnings
Third-quarter net income fell 4% to $137.9 million even as the aggregates margin hit a third-quarter record of 29.6%.
Earnings
The homebuilder grew third-quarter profit and cut leverage, yet narrowed its 2026 closings forecast to 4,600 to 4,800 homes.
SEC Filings
The gene-editing company says cash plus a $200 million credit draw lasts into mid-2029, with cash at $1.0 billion.
SEC Filings
Consolidating the Dutch venture lifted reported results, while adjusted EBITDA fell 13.7% on a rebased basis.
Deals
OppFi says regulators gave it no real chance to address concerns, and it reaffirmed its 2026 revenue outlook of $600 million to $610 million.
Earnings
Adjusted earnings per share fell to $1.42 from $1.48, and the company set fourth-quarter and 2026 guidance while buying back stock.
Earnings
Beam's quarterly collaboration revenue fell to $0.3 million as Biogen moved to end its rights, effective December 2026.
Earnings
Revvity guides fourth-quarter organic growth to about 5%, down from 7% in the third, as its CEO calls AI demand "very early days."
Earnings
Third-quarter revenue reached $321 million, but a $57 million conversion charge produced a net loss and a $1.0 billion stock program followed.
Deals
ADT's third-quarter revenue rose 4% to $1.3 billion, and the company will take no questions on its call because of the $10.00-a-share Thrive deal.
SEC Filings
Upstart's cash fell to $461.5 million as a warehouse line turned uncommitted and its loan-performance disclosure changed.